Yuki Kataoka1, Katsuya Hirano2, Tomoko Narabayashi3, Satoshi Hara4, Daichi Fujimoto5, Tae Tanaka6, Noriyuki Ebi7, Keisuke Tomii5, Hiroshige Yoshioka8. 1. Department of Respiratory Medicine, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan youkiti@gmail.com. 2. Department of Respiratory Medicine, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan. 3. Department of Internal Medicine, Japan Community Health Care Organization Osaka Hospital, Fukushima, Japan. 4. Respiratory Division, Department of Internal Medicine, Itami City Hospital, Itami, Japan. 5. Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan. 6. Department of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki, Japan. 7. Department of Respiratory Medicine, Iizuka Hospital, Iizuka, Japan. 8. Department of Thoracic Oncology, Kansai Medical University Hospital, Hirakata, Japan.
Abstract
AIM: To find new predictive factors for the efficient use of immune checkpoint inhibitors in patients with non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: In this multicenter retrospective cohort study, we evaluated consecutive patients treated with nivolumab between January and October 2016 after second-line systemic chemotherapy. The endpoint was progression-free survival (PFS), as defined by Response Evaluation Criteria in Solid Tumors version 1.1. RESULTS: A total of 189 patients were included in the study. Sixty-four percent had received two or more prior systemic therapies. In Cox proportional hazard analyses, Eastern Cooperative Oncology Group Performance Status of 2 or more, lactate dehydrogenase (LDH) ≥217 mg/dl, and carcinoembryonic antigen ≥13.8 ng/ml were independently associated with inferior PFS. LDH was not associated in the sensitivity analysis. CONCLUSION: In patients with NSCLC treated with nivolumab, worse pretreatment performance status, and higher carcinoembryonic antigen were associated with inferior PFS. Copyright
AIM: To find new predictive factors for the efficient use of immune checkpoint inhibitors in patients with non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: In this multicenter retrospective cohort study, we evaluated consecutive patients treated with nivolumab between January and October 2016 after second-line systemic chemotherapy. The endpoint was progression-free survival (PFS), as defined by Response Evaluation Criteria in Solid Tumors version 1.1. RESULTS: A total of 189 patients were included in the study. Sixty-four percent had received two or more prior systemic therapies. In Cox proportional hazard analyses, Eastern Cooperative Oncology Group Performance Status of 2 or more, lactate dehydrogenase (LDH) ≥217 mg/dl, and carcinoembryonic antigen ≥13.8 ng/ml were independently associated with inferior PFS. LDH was not associated in the sensitivity analysis. CONCLUSION: In patients with NSCLC treated with nivolumab, worse pretreatment performance status, and higher carcinoembryonic antigen were associated with inferior PFS. Copyright
Authors: M G Dal Bello; R A Filiberti; A Alama; A M Orengo; M Mussap; S Coco; I Vanni; S Boccardo; E Rijavec; C Genova; F Biello; G Barletta; G Rossi; M Tagliamento; C Maggioni; F Grossi Journal: J Transl Med Date: 2019-03-08 Impact factor: 5.531
Authors: David Lang; Wolfgang Haslinger; Kaveh Akbari; Mario Scala; Benedikt Hergan; Christian Asel; Andreas Horner; Romana Wass; Elmar Brehm; Bernhard Kaiser; Bernd Lamprecht Journal: Lung Cancer (Auckl) Date: 2020-12-18
Authors: Filippo G Dall'Olio; Francesca Abbati; Francesco Facchinetti; Maria Massucci; Barbara Melotti; Anna Squadrilli; Sebastiano Buti; Francesca Formica; Marcello Tiseo; Andrea Ardizzoni Journal: Ther Adv Med Oncol Date: 2020-10-31 Impact factor: 8.168